



COPY OF PAPERS
ORIGINALLY FILED


UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

Application Number	Filing Date	First Named Applicant	Atty. Docket No.
09/932,183	08/17/2001	Estell, David	GC394C1-US

Genencor International, Inc.
925 Page Mill Road
Palo Alto CA 94034

Title: Proteases from gram-positive organisms



RECEIVED

APR 15 2002

TECH CENTER 1600/2900

Date Mailed: 03/19/2002

JUN 20 2002

RECEIVED

Request for Substitute Papers

The papers filed on 8/7/01 (certificate of mailing dated 11/13/01) are no longer in condition to become part of the permanent records of the United States Patent and Trademark Office (USPTO) for this application (37 CFR 1.52(a)) due to the United States Postal Service sanitization process.

The USPTO requests that applicant provide a copy of the above-identified papers (except for any U.S. or foreign patent documents submitted with the above-identified papers) with a statement that such copy is a complete and accurate copy of the above-identified papers (signing and returning a copy of this notice will provide such a statement). The reply to this letter should be submitted to the USPTO by facsimile at the number indicated **703-308-4556(TC1600)**.

Alternatively, the reply to this letter may be hand-carried to the Customer Service Window located in Room 1B03 of Crystal Plaza Building 2, Arlington, Virginia, 22202.

The USPTO **strongly** prefers that the reply to this letter be submitted by facsimile. However, if applicant cannot submit the reply to this letter by facsimile (or hand-delivery), the reply may be mailed to: Box Duplicate TC1600, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-2327.

This letter is not a notice under 37 CFR 1.251. However, failure to timely replay to this notice within **two (2) weeks** of the date of receipt of this letter may result in the USPTO issuing a notice under 37 CFR 1.251. **A copy of this notice should be included with the reply.**

The enclosed papers are a complete and accurate copy of the above-identified papers.

Name: Kamrin T. MacKnight Registration No.: 38,230

Signature: *Kamrin MacKnight* Date: 4/9/02



COPY OF PAPERS
ORIGINALLY FILED

01-29-02 *SL*

4-12-02

1652
RECEIVED
JUN 20 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the US Postal Services "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail Label No. EL 873071543 US, and addressed to Box Duplicate TC1600, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-2327 on the date shown below:

Date: April 10, 2002

By: *Carol A. See*

Carol A. See

PATENT
Docket No. GC394C1-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	Group Art Unit: 1652
David A. Estell)	
)	
Serial No.: 09/932,183)	Examiner: Unassigned
)	
Filed: August 17, 2001)	
)	
For: Proteases from Gram-Positive)	
Organisms)	

RECEIVED

APR 15 2002

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Box Duplicate TC1600
Commissioner of Patents
Arlington, VA 22202-2327

Sir:


In response to the Request for Substitute Papers dated March 19, 2002, enclosed please find the following documents: Request for Substitute Papers, Associate Power of Attorney, acknowledgement postcard and copies of the following documents previously submitted on November 13, 2001: Transmittal Letter for Notice to Comply (in duplicate), Preliminary Amendment, Statement of Sameness, Notice to Comply, paper copy of sequence listing, and diskette copy of sequence listing.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to

Deposit Account No. 07-1048 (Docket No. GC394C1-US). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: April 10, 2002


Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-5838
Fax: 650-845-6504



I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Box Sequence, Washington, D.C. 20231, on the date shown below.

Date: November 13, 2001

By:

Carol A. See

Carol A. See

COPY OF PAPERS
ORIGINALLY FILED

01/29/02 SB

PATENT

Docket No. GC394C1-US

TECH CENTER 1600/2900

JUN 20 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

David A. Estell

Serial No. 09/932,183

Filed: August 17, 2001

For: Proteases from Gram-Positive
Organisms

Group Art Unit: 1652

Examiner: Unassigned

TRANSMITTAL LETTER FOR NOTICE TO COMPLY

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

Sir:

In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 21, 2001, enclosed please find:


- ☐ a Combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. § 1.16(e);
- ☐ Petition for a _____ Month Extension of Time;
- ☐ Assignment document, Form PTO-1595, and the \$40.00 Assignment Recording Fee;
- ☐ Revocation & New Power of Attorney;
- ☒ Preliminary Amendment
- ☒ Statement of Sameness
- ☒ Paper copy of Sequence Listing (11 pages)
- ☒ Diskette copy of Sequence Listing

- ☐ Request for Use of an Identical Computer Readable Form in Another Application Under 37 CFR § 1.821(e);
- ☒ Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy of Notice to be returned with response);
- ☐ Form PTO-1533 (copy of Notice to be returned with response); and
- ☐ Other: _____
- ☐ Charge \$_____ to Deposit Account No. 07-1048.


The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC394C1-US). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: Nov 13, 2001


Victoria L. Boyd
Registration No. 43,510

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-7615
Fax: 650-845-6504



COPY OF PAPERS
ORIGINALLY FILED

01-29-02 86

UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
Page 1 of 2

JUN 20 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/932,183	08/17/2001	David A. Estell	GC394C1-US

CONFIRMATION NO. 5103

FORMALITIES LETTER



0C00000006S91547

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94034

Date Mailed: 09/21/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE